http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Herceg, Zdenko (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Lee, Ho-Sun,Barraza-Villarreal, Albino,Biessy, Carine,Duarte-Salles, Talita,Sly, Peter D.,Ramakrishnan, Usha,Rivera, Juan,Herceg, Zdenko,Romieu, Isabelle American Physiological Society 2014 PHYSIOLOGICAL GENOMICS Vol.46 No.23
<P>Epigenetic regulation of imprinted genes is regarded as a highly plausible explanation for linking dietary exposures in early life with the onset of diseases during childhood and adulthood. We sought to test whether prenatal dietary supplementation with docosahexaenoic acid (DHA) during pregnancy may modulate epigenetic states at birth. This study was based on a randomized intervention trial conducted in Mexican pregnant women supplemented daily with 400 mg of DHA or a placebo from gestation <I>week 18–22</I> to parturition. We applied quantitative profiling of DNA methylation states at <I>IGF2</I> promoter 3 (<I>IGF2</I> P3), <I>IGF2</I> differentially methylated region (DMR), and <I>H19</I> DMR in cord blood mononuclear cells of the DHA-supplemented group (<I>n</I> = 131) and the control group (<I>n</I> = 130). In stratified analyses, DNA methylation levels in <I>IGF2</I> P3 were significantly higher in the DHA group than the control group in preterm infants (<I>P</I> = 0.04). We also observed a positive association between DNA methylation levels and maternal body mass index; <I>IGF2</I> DMR methylation was higher in the DHA group than the control group in infants of overweight mothers (<I>P</I> = 0.03). In addition, at <I>H19</I> DMR, methylation levels were significantly lower in the DHA group than the control group in infants of normal weight mothers (<I>P</I> = 0.01). Finally, methylation levels at <I>IGF2/H19</I> imprinted regions were associated with maternal BMI. These findings suggest that epigenetic mechanisms may be modulated by DHA, with potential impacts on child growth and development.</P>
-
( Jin Woo Song ),( Kevin K Brown ),( Simon Lf Walsh ),( Anand Devaraj ),( Wim A Wuyts ),( Claudia Valenzuela ),( Rainer-georg Goeldner ),( Susanne Stowasser ),( Rozsa Schlenker-herceg ),( Athol U Well 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Background Several studies have suggested that the progression of fibrosing ILDs is more rapid in patients with a usual interstitial pneumonia (UIP) pattern on HRCT. In the INBUILD trial, nintedanib slowed the rate of decline in FVC in subjects with fibrosing ILDs and a progressive phenotype. We assessed the effect of nintedanib in subgroups by HRCT pattern at baseline. Methods In the INBUILD trial, subjects (n=663) with a progressive fibrosing ILD were randomized to receive nintedanib or placebo. Randomization was stratified by HRCT pattern (UIP-like fibrotic pattern or other fibrotic patterns) based on central review. In pre-specified analyses, we assessed the effects of nintedanib in subgroups of subjects with a UIP-like fibrotic pattern and other fibrotic patterns on HRCT at baseline. Results At baseline, 62.1% of total subjects had a UIP-like fibrotic pattern on HRCT. In subjects who received placebo, the adjusted mean annual rate (SE) of decline in FVC was -209.2 (19.1) mL/year in subjects with a UIP-like fibrotic pattern on HRCT and -155.4 (23.6) mL/year in subjects with other fibrotic patterns on HRCT. The difference between the nintedanib and placebo groups in the annual rate of decline in FVC was 127.8 (95% CI: 74.3, 181.2) mL/year in subjects with a UIP-like fibrotic pattern on HRCT and 75.4 (95% CI: 9.5, 141.4) mL/year in subjects with other fibrotic patterns on HRCT (treatment-by-subgroup-by-time interaction p=0.23) (Table). The effects of nintedanib vs placebo on change from baseline in K-BILD questionnaire total score at week 52, time to acute exacerbation of ILD or death over 52 weeks, and time to death over 52 weeks between the subgroups by HRCT pattern are shown in the Table. Conclusions In the INBUILD trial, the effect of nintedanib on slowing the rate of FVC decline was consistent regardless of fibrotic pattern on HRCT.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
